Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0W0GE
|
|||
| Former ID |
DIB002253
|
|||
| Drug Name |
CR-002
|
|||
| Synonyms |
CR-002 liquid API; Alpha 1 proteinase inhibitor (inhaled solution), CSL Behring; CR-002, CSL Behring
Click to Show/Hide
|
|||
| Indication | Cystic fibrosis [ICD-11: CA25; ICD-10: E84, E84.9; ICD-9: 277] | Phase 1 | [1] | |
| Company |
CSL Behring
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01347190) Safety and Tolerability Study of Liquid Alpha1 Proteinase Inhibitor (API) in Subjects With Cystic Fibrosis. U.S. National Institutes of Health. | |||
| REF 2 | A phase I study of CR002, a fully-human monoclonal antibody against platelet-derived growth factor-D. Int J Clin Pharmacol Ther. 2008 May;46(5):236-44. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.